In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (NASDAQ: OCUL), with a price target of $10. The company’s shares closed yesterday at $6.73.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.8% and a 37.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Ocular Therapeutix is Strong Buy and the average price target is $13.67, representing a 103.1% upside.
In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $22 price target.
See today’s analyst top recommended stocks >>
Based on Ocular Therapeutix’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $13.1 million. In comparison, last year the company had a GAAP net loss of $16.02 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its products include dextenza, sustained release travopost, and posterior segment injections.
